Accepted Manuscript
Insulin-like growth factor-I induces CLU expression through Twist1 to promote
prostate cancer growth
Ario Takeuchi, Masaki Shiota, Eliana Beraldi, Daksh Thaper, Kiyoshi Takahara,
Naokazu Ibuki, Michael Pollak, Michael E. Cox, Seiji Naito, Martin E. Gleave,
Amina Zoubeidi
PII: S0303-7207(14)00016-1
DOI: http://dx.doi.org/10.1016/j.mce.2014.01.012
Reference: MCE 8752
To appear in: Molecular and Cellular Endocrinology Molecular
and Cellular Endocrinology
Received Date: 19 June 2013
Revised Date: 27 December 2013
Accepted Date: 14 January 2014
Please cite this article as: Takeuchi, A., Shiota, M., Beraldi, E., Thaper, D., Takahara, K., Ibuki, N., Pollak, M., Cox,
M.E., Naito, S., Gleave, M.E., Zoubeidi, A., Insulin-like growth factor-I induces CLU expression through Twist1
to promote prostate cancer growth, Molecular and Cellular Endocrinology Molecular and Cellular
Endocrinology (2014), doi: http://dx.doi.org/10.1016/j.mce.2014.01.012
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1
Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer
growth
Ario Takeuchi1, Masaki Shiota1, Eliana Beraldi1, Daksh Thaper1, Kiyoshi Takahara1, Naokazu Ibuki1,
Michael Pollak2, Michael E. Cox1, Seiji Naito3, Martin E. Gleave1, and Amina Zoubeidi1
1The Vancouver Prostate Centre and Department of Urologic Sciences, University of British
Columbia, Vancouver, British Columbia, Canada
2Department of Medicine and Oncology, McGill University, Montreal, Quebec, Canada
3Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Short title: IGF-I induces CLU via Twist1
Keywords: clusterin; insulin-like growth factor-I; prostate cancer; STAT3; Twist1
Corresponding Author:
Dr. Amina Zoubeidi
The Vancouver Prostate Centre and Department of Urologic Sciences,
University of British Columbia,
2660 Oak Street, Vancouver, British Columbia, Canada V6H 3Z6.
Phone: +1-604-875-4818
Fax: +1-604-875-5654
E-mail: [email protected]
2
ABSTRACT
Clusterin (CLU) is cytoprotective molecular chaperone that is highly expressed in
castrate-resistant prostate cancer (CRPC). CRPC is also characterized by increased insulin-like
growth factor (IGF)-I responsiveness which induces prostate cancer survival and CLU expression.
However, how IGF-I induces CLU expression and whether CLU is required for IGF-mediated growth
signaling remain unknown. Here we show that IGF-I induced CLU via STAT3-Twist1 signaling
pathway. In response to IGF-I, STAT3 was phosphorylated, translocated to the nucleus and bound to
the Twist1 promoter to activate Twist1 transcription. In turn, Twist1 bound to E-boxes on the CLU
promoter and activated CLU transcription. Inversely, we demonstrated that knocking down Twist1
abrogated IGF-I induced CLU expression, indicating that Twist1 mediated IGF-I–induced CLU
expression. When PTEN knockout mice were crossed with lit/lit mice, the resultant IGF-I deficiency
suppressed Twist1 as well as CLU gene expression in mouse prostate glands. Moreover, both Twist1
and CLU knockdown suppressed prostate cancer growth accelerated by IGF-I, suggesting the
relevance of this signaling not only in an in vitro, but also in an in vivo. Collectively, this study
indicates that IGF-I induces CLU expression through sequential activation of STAT3 and Twist1, and
suggests that this signaling cascade plays a critical role in prostate cancer pathogenesis.
3
Introduction
Prostate cancer is the most common solid malignant tumor among males in Western countries
(Jemal et al., 2010). A series of epidemiological and biological studies demonstrate that the
insulin-like growth factor (IGF) axis is a critical regulator of growth, survival, and metastatic potential
in a variety of malignancies and is closely implicated in prostatic carcinogenesis and prostate cancer
progression as well as resistance to castration therapy (Chan et al., 1998; Krueckl et al., 2004;
Nickerson et al., 2001; Wolk et al., 1998). We have previously demonstrated that IGF-I promoted
human prostate cancer cell growth and that increased IGF-I receptor (IGF-IR) expression and
signaling are components of castrate resistant progression (Krueckl et al., 2004; Takahara et al.,
2011).
IGFs bind to the tyrosine kinase IGF-IR, which is a heterotetrameric type I receptor
protein-tyrosine kinase composed of two ligand-binding α-subunits and two transmembrane
β-subunits. The binding of ligand to IGF-IR induces auto-phosphorylation of the β-subunits of the
receptor complex and further activation of the protein-tyrosine kinase activity (Hubbard et al., 1994;
Weiss & Schlessinger 1998). Once activated, IGF-IR recruits and phosphorylates various downstream
targets such as the insulin receptor substrate-1 and -2 which activate many signaling pathways,
including Ras/Raf/mitogen-activated protein kinase (MAPK) and PI3K/Akt, as well as signal
transducer and activator of transcription 3 (STAT3; Zong et al., 2000) resulting in cell growth and
survival.
Clusterin (CLU) is a stress-induced cytoprotective chaperone, and involved in many biological
processes such as sperm maturation, tissue differentiation, tissue remodeling, membrane recycling,
lipid transportation, cell proliferation and cell death. CLU has been shown expressed in many human
cancers (Zhong et al., 2010). Increased levels of CLU have been reported in breast, colon, lung,
bladder, prostate and other cancers (July et al., 2004; Kevans et al., 2009; Miyake et al., 2002; So et
al., 2005; Steinberg et al., 1997). In prostate, CLU levels are low in benign prostate epithelial cells,
but increase in prostate cancers with higher Gleason grade (Steinberg et al., 1997). Furthermore, CLU
4
expression increases as prostate cancers adapt to androgen-deprivation therapy (July et al., 2002).
These data indicate that CLU is also implicated in prostate carcinogenesis and prostate cancer
progression. Similarly, numerous evidences showed that a basic helix–loop–helix transcription factor
Twist1 is also involved in pathogenesis of various cancers (Franco et al., 2011), including castration
resistance in prostate cancer (Shiota et al., 2010).
IGF-I axis induced CLU expression after irradiation via Src-MEK-ERK-EGR1 signaling in
human breast cancer MCF-7 cells (Criswell et al., 2005). However, the mechanism and role of CLU
induction by IGF-I in prostate cancer remain unrevealed. In this study, we set out to define links
between IGF-I signaling and Twist1/CLU expression in prostate cancer, identifying STAT3 as a
downstream effector of IGF-I.
5
MATERIAL AND METHODS
Cell culture and transfection
The human prostate cancer cell line, PC-3, was purchased from the American Type Culture
Collection (ATCC authentication by isoenzymes analysis) and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM; Thermo Scientific, Waltham, MA, USA) supplemented with 5%
fetal-bovine serum (FBS). The human prostate cancer cell line LNCaP was kindly provided by Dr.
Leland W.K. Chung (Cedars-Sinai Medical Center, Los Angeles, CA, USA), tested and authenticated
by whole-genome and whole-transcriptome sequencing on Illumina Genome Analyzer IIx platform in
2009. LNCaP cells were maintained in RPMI 1640 (Thermo Scientific) supplemented with 5% FBS.
Antibodies and reagents
Antibodies against Myc (sc-815), CLU (sc-6419) and Twist1 (sc-81417) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phosphorylated STAT3Tyr705 (p-STAT3Tyr705,
#9131), anti-phosphorylated STAT3Ser727 (p-STAT3Ser727, #9134) and anti-STAT3 (#9139) antibodies
were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-Lamin B1 and
anti-β-actin antibodies were purchased from Abcam (Cambridge, MA, USA) and Sigma (St Louis,
MO, USA), respectively. Human recombinant IGF-I was obtained from Fitzgerald (Acton, MA,
USA).
Plasmids and siRNAs
Twist1-Myc-Flag plasmid expressing C-terminally Myc-Flag-tagged Twist1 protein and the
corresponding mock plasmid (Myc-Flag plasmid) were purchased from OriGene (Rockville, MD,
USA). The Twist1 reporter plasmid (Twist–Luc) was kindly provided from Dr. Wang LH (Mount
Sinai School of Medicine, New York, NY, USA; Cheng et al., 2008). CLU reporter plasmids
(CLU–Luc –1,998/+254, –1,998/–702, –1,116/–702, and –707/+254) containing various lengths of the
promoter and first exon of the wild-type human CLU gene were constructed as described previously
(Shiota et al., 2011).
The following double-stranded 25-bp siRNA oligonucleotides were commercially generated
6
(Invitrogen, Carlsbad, CA, USA): 5’-CUUCCUCGCUGUUGCUCAGGCUGUC-3’ for Twist1
siRNA #1; 5’-UUGAGGGUCUGAAUCUUGCUCAGCU-3’ for Twist1 siRNA #2. The sequence of
siRNA corresponding to the human CLU initiation site in exon II was
5’-GCAGCAGAGUCUUCAUCAU-3’ (Dharmacon Research Inc.). Stealth™ RNAi Negative
Control Medium GC Duplex #2 (Invitrogen) was used as a control siRNA. Cells were transfected
with the indicated siRNA or the indicated plasmid as previously described (Zoubeidi et al., 2010a;
Zoubeidi et al., 2010b).
Quantitative reverse transcription (RT)-PCR
RNA extraction and RT-PCR were performed as described previously (Lamoureux et al., 2011).
Real time monitoring of PCR amplification of cDNA was performed using the following primer pairs
and probes, Twist1 (Hs00361186_m1), CLU (Hs00156548_m1) and GAPDH (Hs03929097_g1)
(Applied Biosystems) on ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems)
with TaqMan Gene Expression Master Mix (Applied Biosystems). Target gene expression was
normalized to GAPDH levels in respective samples as an internal control. The results are
representative of at least three independent experiments.
Western blot analysis
Whole-cell extracts were obtained by lysis of cells in an appropriate volume of ice-cold RIPA
buffer composed of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet
P-40, 0.1% sodium dodecyl sulfate (SDS) containing 1 mM Na3VO4, 1 mM NaF, 1 mM
phenylmethylsulfonyl fluoride and protease inhibitor cocktail tablets (Complete, Roche Applied
Science, Indianapolis, IN, USA). Nuclear and cytoplasmic extracts were obtained using CelLyticTM
NuCLEARTM Extraction Kit (Sigma) according to manufacturer’s protocol. Cellular extracts were
clarified by centrifugation at 13,000 x g for 10 min and protein concentrations of the extracts
determined by a BCA protein assay kit (Thermo Scientific). Thirty micrograms of the extracts were
boiled for 5 min in SDS sample buffer, separated by SDS-PAGE, and transferred onto a
polyvinylidene difluoride (PVDF) membrane. Membranes were probed with dilutions of primary
7
antibodies followed by incubation with horseradish peroxidase-conjugated secondary antibodies.
After extensive washing, proteins were visualized by a chemiluminescent detection system (GE
Healthcare, Buckinghamshire, UK).
Luciferase reporter assay
Prostate cancer cells were transfected with 0.5 μg of the indicated reporter plasmid, expression
plasmid, siRNA, and 0.05 μg of pRL-TK as an internal control. 24 hours post transfection, media was
changed to serum-free media followed by IGF-I treatment. The luciferase activities were measured
using a Dual-Luciferase Reporter Assay System (Promega) and a microplate luminometer (EG&G
Berthold). The Firefly luciferase activities were corrected by the corresponding Renilla luciferase
activities and protein concentration. The results are representative of at least three independent
experiments.
Chromatin immunoprecipitation assay (ChIP assay)
LNCaP cells were seeded and stimulated with 100 ng/ml IGF-I followed by paraformaldehyde
cross-linking and micrococcal nuclease digestion to achieve a DNA smear of 200–1000 bp. ChIP
assay on the indicated genes was performed using SimpleChIPTM Enzymatic Chromatin IP Kit
(Agarose Beads) according to the manufacturer’s protocol (Cell Signaling Technology). Quantitative
RT-PCR assay was performed using ABI PRISM 7900 HT Sequence Detection System with 2 μL of
20 μL DNA extraction, the primer pairs below and RT2 Real-TimeTM SYBR Green/Rox PCR master
mix (Qiagen, Valencia, CA, USA). The results are representative of at least three independent
experiments. The primer pairs for Twist1 promoter were Fw; 5’-TGCCTTTCCCATGGACTGGG-3’
and Rv; 5’-GAGTTCCAAAGGCCAAACCG-3’ as described previously (Cheng et al. 2008). The
primer pairs for CLU –02 (GPH025704(–)02A) targeting around –1,403 bp, CLU –01
(GPH025704(–) 01A) targeting around –417 bp, CLU +07 (GPH025704(+)07A) targeting around
+6,603 bp, and RPL30 gene (exon 3) were described previously (Shiota et al., 2011).
Production and characterization of Ghrhr(lit/lit)/Cre/PTEN(fl/fl)
The production of Ghrhr(lit/lit)/Cre/PTEN(fl/fl) was previously described (Takahara et al.,
8
2013). Briefly, we crossed pbARR2-Cre, PTEN (fl/fl) mice (Wang et al., 2003) with GHRHR (lit/lit)
mice (Yang et al., 1996) to produce lit/lit and lit/+ PTEN-/- mice. Mice serums and prostates were
harvested in accordance with the guidelines of the Canadian Council on Animal Care and with
appropriate institutional certification between 15 and 20 weeks of age. Nineteen mice were collected
for each cohort after genotyping to clarify lit heterozygosity (lit/+) and homozygosity (lit/lit), Cre
recombinase and PTEN fl/fl status from tail clip DNA. Serum IGF-I levels were measured using
ELISA from (R&D Systems, Minneapolis, MN, USA). Murine Twist1 (Mm00442036_m1) and
murine CLU (Mm00442773_m1) transcript levels were measured using RNA from mice prostates by
quantitative RT-PCR normalized to murine GAPDH (Mm99999915_g1) transcript levels.
Cell growth assay
LNCaP cells (2.5 x 104) transfected with 10 nM of the indicated siRNA were plated in 24-well
plates. The following day, media were changed into media supplemented with 1% serum from lit/lit or
lit/+ mice with or without 100 ng/mL IGF-I. After incubation for 96 h, cell growth was measured
using the crystal violet assay as described previously (Shiota et al., 2011). The results are
representative of at least 3 independent experiments.
Immunohistochemistry
Prostate tissues from PTEN knockout lit/lit mice and PTEN knockout lit/+ mice at 15 and 20
weeks of age were obtained in accordance with the guidelines of the Canadian Council on Animal
Care and with appropriate institutional certification. Immunohistochemical staining was conducted as
previously described (Zoubeidi et al., 2010b) using the Ventana Discover XT TM autostainer (Ventana
Medical System, Tuscan, AZ, USA) with enzyme labeled biotin streptavidin system and solvent
resistant DAB Map kit by antibodies against CLU (Santa Cruz Biotechnology), IGF-IR (Sigma),
p-STAT3Tyr705 (Cell Signaling Technology), Twist1 (Sigma).
Statistical analysis
All data were assessed using the Student’s t-test. Levels of statistical significance were set at P
< 0.05.
10
RESULTS
IGF-I induces both Twist1 and CLU expression in prostate cancer cells
It is known that IGF-I activates Twist1 in NIH-3T3 fibroblasts (Dupont et al., 2001) and CLU
expression in breast cancer cell lines (Criswell et al., 2005). Since Twist1 is a transcription factor, we
intended to determine whether IGF-I induced CLU expression via Twist1 in human prostate cancer
cells. First, we examined the appropriate concentration inducing Twist1 and CLU expression in
LNCaP and PC-3 cells. Then, 100 ng/mL IGF-I most induced Twist1 as well as CLU expression both
in LNCaP and PC-3 cells (data not shown). Then, we chose 100 ng/ml IGF-I for treatment thereafter.
Next, LNCaP and PC-3 cell lines were treated with IGF-I in a time dependent manner and both
Twist1 and CLU expression were evaluated at mRNA and protein levels. We found that IGF-I
increased Twist1 as well as CLU expression at transcript level (Fig. 1A) and protein level (Fig. 1B) in
LNCaP and PC-3 cells.
Twist1 binds to CLU promoter region and regulates CLU expression
The finding above prompted us to examine the functional link between Twist1 transcription
factor and CLU. As shown in Fig. 2A, Twist1 knockdown using 2 different Twist1-specific siRNAs
reduced basal CLU expression at both transcript and protein levels in LNCaP cells. Inversely, Twist1
over-expression up-regulated CLU mRNA and protein expression (Fig. 2B).
Since Twist1 is known as an E-box (5’-CANNTG-3’) binding transcription factor (Li et al.,
1995), we investigated whether Twist1 directly regulates CLU transcription. We first searched for
putative E-box binding sites in the CLU promoter region between –2,000 bp and +500 bp from
transcription start site (TSS) and found that are 10 E-boxes in CLU promoter as shown in Fig. 2C. We
next analyzed CLU promoter activity using different truncated regions (Fig. 2C). We found that CLU
promoter activity was highest between –1,998 bp and –702 bp in LNCaP cells which contains 7
E-boxes (Fig. 2D) as a potential Twist1-binding sites, similarly to the result using PC-3 cells (Shiota
et al., 2012). To further evaluate if Twist1 can regulates CLU promoter activity, Twist1 was
overexpressed and CLU transcriptional activity was analyzed using different CLU promoter
11
constructs. As shown in Fig. 2E, Twist1 increased luciferase activity of CLU–Luc –1,998/–702, but
not CLU–Luc –1,116/–702. These findings suggested that the cis-element of CLU promoter region
containing –1,998/–1,116 bp was activated by Twist1. Inversely, Twist1 knockdown reduced CLU
promoter transcriptional activity (Fig. 2F). To confirm Twist1 binding to CLU promoter region, we
performed ChIP assay against CLU gene in LNCaP cells. The results showed that Twist1 bound to
CLU promoter regions around –1,400 bp from TSS represented by CLU –02, while they did not bind
to the CLU gene regions around +6,600 bp from TSS and RPL30 gene (Fig. 2G).
IGF-I induces CLU expression via Twist1
To further evaluate whether Twist1 expression is required for IGF-I–induced CLU expression,
Twist1 was silenced and levels of Twist1 and CLU were evaluated in the absence or presence of
IGF-I. Twist1-specific siRNA successfully down-regulated both basal and IGF-I–induced Twist1
expression (Fig. 3A, left) as well as CLU mRNA at basal level. Interestingly, we found that Twist1
knockdown abrogated IGF-I–induced CLU expression at mRNA levels (Fig. 3A, right) and protein
levels (Fig. 3B) in both LNCaP and PC-3 cells. These data suggest that Twist1 is involved in basal
CLU expression, as well as required for IGF-I–induced CLU expression. In addition, luciferase
reporter assay using CLU reporter plasmid also revealed that Twist1 knockdown ameliorated CLU
induction by IGF-I (Fig. 3C).
IGF-I activates STAT3 transcription factor, resulting in Twist1 up-regulation
To investigate the mechanism of Twist1/CLU induction by IGF-I, we focused on STAT3
transcription factor because it was reported that STAT3 transcriptionally regulated Twist1 expression
(Cheng et al., 2008). We next analyzed the effect of IGF-I on STAT3 phosphorylation. Our data
showed that IGF-I induces STAT3 phosphorylation only on Tyr705 but not on Ser727, resulting in an
activation of STAT3 (Fig. 4A). This result was supported by the finding that IGF-I facilitated STAT3
translocation into nucleus (Fig. 4B). As a result, IGF-I stimulated STAT3 binding to Twist1-promotor
region, resulting in activation of Twist1 transcription (Fig. 4C), thereby augmented Twist1 binding to
CLU-promoter region (Fig. 4D). Consistently, reporter assay using Twist1 reporter plasmid showed
12
an increased transcription of Twist1 gene by IGF-I (Fig. 4E). These data show that IGF-I promoted
STAT3 activation and STAT3 is at least in part needed to mediate the IGF-I–induced Twist1
expression and subsequent CLU expression.
IGF-I/Twist1/CLU signaling plays a critical role in mice prostate cancer proliferation
To investigate the biologic relevance of the above findings, we assessed Twist1 and CLU
expression in prostate tissues from PTEN knockout mice (Wang et al., 2003) crossed with lit/lit mice,
which harbor growth-hormone-releasing hormone receptor (GHRHR) mutation abolishing GHRHR
function (Wang et al., 2003). Lack of growth-hormone-releasing hormone signaling in lit/lit mice
results in marked reduction of serum growth hormone, which in turn leads to reducing serum IGF-I
level (Fig. 5A), known to correlate with IGF-I level in prostate (Wang et al., 2008). Consistently with
the preceding in vitro data, Twist1 and CLU expression were lower in prostate tissues, harvested
between 15 and 20 weeks of age, from PTEN knockout lit/lit mice compared with those of PTEN
knockout lit/+ mice (Fig. 5B). As well, immunohistochemistry against prostate tissues from PTEN
knockout lit/lit mice and PTEN knockout lit/+ mice suggested that prominent decreased levels of
IGF-IR and Twist1 in lit/lit mice (Fig. 5C).
Previously we showed that prostate cancer grew less rapidly in lit/lit mice compared with lit/+
mice in an in vitro as well as an in vivo (Takahara et al., 2011). Subsequently, we examined whether
cell proliferation induced by IGF-I is affected by Twist1 or CLU silencing. As we previously reported,
LNCaP cell growth was promoted by IGF-I, while this growth promotion was almost completely
abolished by either Twist1 or CLU knockdown (Fig. 6A), suggesting that both Twist1 and CLU are
important downstream mediators of IGF-I–induced prostate cancer growth.
13
DISCUSSION
In this study, we identified a novel mechanism by which IGF-I regulates CLU expression in
prostate cancer cells via the STAT3-Twist1 pathway. We went on to demonstrate that once IGF-I
activates STAT3, STAT3 translocates to the nucleus, binds to the Twist1 promoter, resulting in
Twist1 up-regulation. Twist1 subsequently binds to E-boxes on CLU promoter and enhance CLU
expression, thereby creating a feed-forward loop which leads to increase of cell proliferation in
prostate cancer (Fig. 6B).
Our data showed that IGF-I induced STAT3 phosphorylation in prostate cancer cells,
confirming previous reports in human fibroblasts (HEK293T cells; Zong et al., 2000) and suggesting
that the role of IGF-I on STAT3 activation was conserved across different cell lines. Once
phosphorylated, STAT3 translocated to the nucleus and regulated Twist1 expression in breast cancer
cells (Cheng et al., 2008). STAT3 activation positively correlated with Twist1 expression in breast
cancer tissues (Cheng et al., 2008). Similarly, epidermal-growth factor (EGF)–induced Twist1
transcription was reported to be mediated by STAT3 in several cancer cells (Lo et al., 2007).
Moreover, in hepatocellular carcinoma, activated STAT3 and Twist1 expressions were positively
correlated (Zhang et al., 2012). Thus, the connection between STAT3 and Twist1 has been established
in various cancers including prostate cancer (Cheng et al., 2008; Cho et al., 2013; Hsu et al., 2012;
Teng et al., 2013). Additionally, in this study, STAT3 phosphorylation at Tyr705 was induced by
IGF-I concurret with nuclear translocation, which is consistent with the previous report (Wen et al.,
1995). Moreover, we found that STAT3 bound to Twist1 promoter region in prostate cancer, leading
to Twist1 gene expression, which was increased by IGF-I treatment.
Twist1, a basic helix–loop–helix transcription factor, has been described as a proto-oncogene
(Hamamori et al., 1997; Quertermous et al., 1994) that promoted breast cancer metastasis (Yang et al.,
2004). Similar to CLU, Twist1 was also up-regulated in various malignant tumors, including prostate
cancer (Wallerand et al., 2010; Wang et al., 2004). Moreover, we have recently shown that Twist1
was involved in prostate cancer growth (Shiota et al., 2008) as well as resistance to castration through
14
androgen receptor (Shiota et al., 2010). Collectively, Twist1 plays a key role in the development and
progression of prostate cancer similar to that ascribed to CLU. Like Twist1 (Dupont et al., 2001),
CLU was also known to be induced by IGF-I (Criswell et al., 2005). In this study, Twist1 knockdown
decreased basal CLU transcript and protein, as well as IGF-I–induced CLU expression, indicating that
IGF-I–induced CLU expression was mediated by Twist1. Furthermore, we found that Twist1
regulated CLU transcription by reporter assay and ChIP assay. These findings link Twist1 regulation
of CLU expression, under IGF-I stimulation, as a potential pathway that promotes prostate cancer
growth.
The pbARR2-Cre, PTEN (fl/fl) mouse model, which lead to de novo formation of prostate
tumors, is one model that mimicks human prostate cancer from initiation to local invasion and
metastasis (Trotman et al., 2003; Wang et al., 2003). Prostate-specific loss of PTEN expression
resulted in invasive carcinoma with lymphovascular invasion within 12 weeks, which progressed to
lung metastasis (Wang et al., 2003). Deletion or mutation of the tumor suppressor PTEN gene has
been implicated in many human cancers and has been seen in up to 30% of primary prostate cancers
and >64% of prostate metastases, making PTEN an important candidate gene for prostate cancer
development and progression (Majumder & Sellers 2005; Suzuki et al., 1998). Furthermore, CLU
expression was elevated in PTEN knockout mice (Wang et al., 2003). To define links between IGF-I
signaling and CLU in prostate cancer growth, we crossed pbARR2-Cre, PTEN (fl/fl) mice with
GHRHR (lit/lit) mice. It has been known that in lit/lit mice, several proto-oncogenic pathways
including MAPK and PI3K/Akt were down-regulated (Takahara et al., 2011). In addition, in PTEN
knockout lit/lit mice model, Twist1 as well as CLU expression was reduced in IGF-1–deficient lit/lit
mice, which supported our in vitro data that IGF-I induced Twist1 and CLU expression in LNCaP and
PC-3 cells. Furthermore, this study suggested that Twist1 as well as CLU plays key roles in
IGF-1–induced prostate cancer cell proliferation. Since IGF-I has been a well-known promoter of
prostate cancer growth, these data identified Twist1 and CLU as important mediators of
IGF-I–stimulated prostate pathogenesis in this model.
15
In summary, we identified a novel Twist1/CLU pathway stimulated by IGF-I involving STAT3
phosphorylation, and then CLU. Therefore, signaling from IGF-I to CLU provided a molecular
mechanism that might explain at least in part the influence of IGF-I on prostate cancer.
16
Declaration of interest
There are no conflicts of interest.
Funding
This study was supported by the Terry Fox New Frontiers Program, the Canadian Institutes of Health
Research, the Prostate Cancer Foundation USA.
Acknowledgements
We are grateful to Dr. Lu-Hai Wang (Mount Sinai School of Medicine, New York, NY, USA)
providing the Twist–Luc reporter plasmid. We thank Howard Tearle and Ladan Fazli1 for their
excellent technical assistance.
17
REFERENCE
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M
1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279
563–566
Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ &
Wang LH 2008 Twist is transcriptionally induced by activation of STAT3 and mediates STAT3
oncogenic function. J Biol Chem 283 14665–14673
Cho KH, Jeong KJ, Shin SC, Kang J, Park CG & Lee HY 2013 STAT3 mediates TGF-β1-induced
TWIST1 expression and prostate cancer invasion. Cancer Lett 336 167–173
Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD & Boothman DA 2005 Delayed
activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin
expression, a pro-survival factor. J Biol Chem 280 14212–14221
Dupont J, Fernandez AM, Glackin CA, Helman L & LeRoith D 2001 Insulin-like growth factor 1
(IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J
Biol Chem 276 26699–26707
Franco HL, Casasnovas J, Rodríguez-Medina JR & Cadilla CL 2011 Redundant or separate
entities?―roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic
Acids Res 39 1177–1186
Hamamori Y, Wu HY, Sartorelli V & Kedes L 1997 The basic domain of myogenic basic
helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein,
Twist. Mol Cell Biol 17 6563–6573
Hsu KW, Hsieh RH, Huang KH, Fen-Yau Li A, Chi CW, Wang TY, Tseng MJ, Wu KJ & Yeh TS 2012
Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression.
Carcinogenesis 33 1459–1467
Hubbard SR, Wei L, Ellis L & Hendrickson WA 1994 Crystal structure of the tyrosine kinase domain
of the human insulin receptor. Nature 372 746–754
18
Jemal A, Siegel R, Xu J & Ward E 2010 Cancer statistics, 2010. CA Cancer J Clin 60 277–300.
July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL & Gleave ME 2002 Clusterin expression
is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate
50 179–188
July LV, Beraldi E, So A, Fazli L, Evans K, English JC & Gleave ME 2004 Nucleotide-based
therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in
vivo. Mol Cancer Ther 3 223–232
Kevans D, Foley J, Tenniswood M, Sheahan K, Hyland J, O'Donoghue D, Mulcahy H & O'Sullivan J
2009 High clusterin expression correlates with a poor outcome in stage II colorectal cancers.
Cancer Epidemiol Biomarkers Prev 18 393–399
Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME & Cox ME 2004
Increased insulin-like growth factor I receptor expression and signaling are components of
androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer
Res 64 8620–8629
Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A & Gleave ME 2011
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by
suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res 71
5838–5849
Li L, Cserjesi P & Olson EN 1995 Dermo-1: a novel twist-related bHLH protein expressed in the
developing dermis. Dev Biol 172 280–292
Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN & Hung MC 2007
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription
3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene
expression. Cancer Res 67 9066–9076
Majumder PK & Sellers WR 2005 Akt-regulated pathways in prostate cancer. Oncogene 24
7465–7474
19
Miyake H, Gleave M, Kamidono S & Hara I 2002 Overexpression of clusterin in transitional cell
carcinoma of the bladder is related to disease progression and recurrence. Urology 59 150–154
Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL & Pollak M 2001 In vivo progression of
LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with
increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer
Res 61 6276–6280
Quertermous EE, Hidai H, Blanar MA & Quertermous T 1994 Cloning and characterization of a basic
helix-loop-helix protein expressed in early mesoderm and the developing somites. Proc Natl Acad
Sci U S A 91 7066–7070
Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Yokomizo A, Naito S &
Kohno K 2008 Twist promotes tumor cell growth through YB-1 expression. Cancer Res 68
98–105
Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T & Naito
S 2010 Castration resistance of prostate cancer cells caused by castration-induced oxidative stress
through Twist1 and androgen receptor overexpression. Oncogene 29 237–250
Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S, Zoubeidi A & Gleave ME 2012
Clusterin mediates TGF-β–induced epithelial-mesenchymal transition and metastasis via Twist1 in
prostate cancer cells. Cancer Res 72 5261–5272
Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, Sorensen PH & Gleave ME 2011
Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate
cancer. Mol Cancer Res 9 1755–1766
So A, Sinnemann S, Huntsman D, Fazli L & Gleave M 2005 Knockdown of the cytoprotective
chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol
Cancer Ther 4 1837–1849
Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM & Sensibar JA 1997
Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin
20
Cancer Res 3 1707–1711
Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB & Bova GS 1998
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer
tissues. Cancer Res 58 204–209
Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M & Cox ME 2011 Human prostate cancer
xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. Prostate
71 525–537
Takahara K, Ibuki N, Ghaffari M, Tearle H, Ong CJ, Azuma H, Gleave ME, Pollak M & Cox ME
2013 The influence of growth hormone/insulin-like growth factor deficiency on prostatic
dysplasia in pbARR2-Cre, PTEN knockout mice. Prostate Cancer Prostatic Dis 16 239–247
Teng J, Wang X, Xu Z & Tang N 2013 HBx-dependent activation of Twist mediates STAT3 control of
epithelium-mesenchymal transition of liver cells. J Cell Biochem 114 1097–1104
Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P,
Greenberg NM, Van Dyke T, Cordon-Cardo C & Pandolfi PP 2003 Pten dose dictates cancer
progression in the prostate. PLoS Biol 1 E59
Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE & Ferrière JM 2010 The
epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced
and/or metastatic bladder and prostate cancers. Urol Oncol 28 473–479
Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS,
Liu X & Wu H 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to
metastatic prostate cancer. Cancer Cell 4 209–221
Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT & Wong YC 2004 Identification of a
novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in
human cancer cells. Oncogene 23 474–482
Wang Z, Luque RM, Kineman RD, Ray VH, Christov KT, Lantvit DD, Shirai T, Hedayat S, Unterman
TG, Bosland MC, Prins GS & Swanson SM 2008 Disruption of growth hormone signaling retards
21
prostate carcinogenesis in the Probasin/TAg rat. Endocrinology 149 1366–1376
Weiss A & Schlessinger J 1998 Switching signals on or off by receptor dimerization. Cell 94 277–280
Wen Z, Zhong Z & Darnell JE Jr 1995 Maximal activation of transcription factor by Stat1 and Stat3
requires both tyrosine and serine phosphorylation. Cell 82 241–250
Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, Adami HO &
richopoulos D 1998 Insulin-like growth factor 1 and prostate cancer risk: a population-based,
case-control study. J Natl Cancer Inst 90 911–915
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I,
Richardson A & Weinberg RA 2004 Twist, a master regulator of morphogenesis, plays an essential
role in tumor metastasis. Cell 117 927–939
Yang XF, Beamer WG, Huynh H & Pollak M 1996 Reduced growth of human breast cancer
xenografts in hosts homozygous for the lit mutation. Cancer Res 56 1509–1511
Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ren WH, Ge YS, Yu JH, Liu WB & Wang W 2012
Activation of STAT3 signal pathway correlates with Twist and E-cadherin expression in
hepatocellular carcinoma and their clinical significance. J Surg Res 174 120–129
Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S
& Djeu JY 2010 Induction of clusterin by AKT--role in cytoprotection against docetaxel in
prostate tumor cells. Mol Cancer Ther 9 1831–1841
Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB & Wang LH 2000 Mechanism of STAT3
activation by insulin-like growth factor I receptor. J Biol Chem 275 15099–15105
Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, Nelson CC, Rennie PS &
Gleave ME 2010a Clusterin facilitates COMMD1 and I-κB degradation to enhance NF-κB
activity in prostate cancer cells. Mol Cancer Res 8 119–130
Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L & Gleave ME 2010b Hsp27
promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent
phosphorylation and inactivation of BAD. Cancer Res 70 2307–2317
23
FIGURE LEGENDS
Figure 1. IGF-I increases Twist1 expression followed by CLU up-regulation. (A) LNCaP (left) and
PC-3 (right) cells were treated with 100 ng/mL IGF-I. After the indicated duration, quantitative
RT-PCR was performed using the primer pairs and probes for Twist1, CLU and GAPDH. Each
transcript level from non-treated cells was set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with
no treatment). (B) LNCaP (left) and PC-3 (right) cells were treated with 100 ng/mL IGF-I. After the
indicated duration, whole-cell extracts were analyzed by SDS–PAGE and western blot analysis with
specific antibodies.
Figure 2. Twist1 binds to CLU promoter region and regulates CLU expression. (A) LNCaP cells were
transfected with 40 nM of the indicated siRNA. At 72 h after transfection, quantitative RT-PCR was
performed using the primers and probes for Twist1, CLU and GAPDH. Each transcript level from
cells transfected with control siRNA was set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with
control siRNA). Whole-cell extracts were analyzed by SDS–PAGE and western blot analysis with
specific antibodies. (B) LNCaP cells were transfected with 1.0 μg/mL of the indicated expression
plasmid. At 72 h after transfection, quantitative RT-PCR was performed using the primers and probes
for CLU and GAPDH. Each transcript level from mock-transfected cells was set as 1. Boxes, mean;
bars, ±s.d. *P < 0.05 (compared with mock). Whole-cell extracts were analyzed by SDS–PAGE and
western blot analysis with specific antibodies. (C) Schematic representation of the promoter region
and 5’ end of the CLU gene. Black box, E-boxes (5’-CANNTG-3’); gray box, CLE; white box,
AP-1–binding site. CLU–Luc plasmids (–1,998/+254, –1,998/–702, –1,116/–702, and –707/+254)
used in (d), (e) and (f) are shown. (D) LNCaP cells were cotransfected with 0.5 μg/mL of the various
CLU–Luc plasmids and 0.05 μg/mL of pRL-TK. The luciferase activity of CLU–Luc –1,998/+254
was set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with CLU-Luc –1,998/+254). (E) LNCaP
cells were cotransfected with 0.5 μg/mL of the various CLU–Luc plasmids, 0.5 μg/mL of Myc-Flag or
24
Twist1–Myc-Flag expression plasmid and 0.05 μg/mL of pRL-TK. The luciferase activity of
CLU–Luc with mock plasmid was set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with mock).
(F) LNCaP cells were cotransfected with 0.5 μg/mL of the CLU–Luc –1,998/+254 plasmid, 20 nM of
the indicated siRNA and 0.05 μg/mL of pRL-TK. The luciferase activity of CLU–Luc –1,998/+254
alone was set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with control siRNA). (G) ChIP
assays were conducted on nuclear extracts from LNCaP cells using the indicated antibodies. The
quantitative RT-PCR was carried out using� immunoprecipitated DNAs, soluble� chromatin, and
specific primer pairs for the CLU and RPL30 genes: CLU –02 targeting around –1,403 bp from TSS,
CLU –01 targeting around –417 bp from TSS, CLU +07 targeting around +6,603 bp from TSS and
RPL30 as negative control. The results of immunoprecipitated samples were corrected for the results
of the corresponding soluble chromatin samples. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with
IgG).
Figure 3. IGF-I induces CLU expression via Twist1. (A) LNCaP (left) and PC-3 (right) cells were
transfected with 40 nM of the indicated siRNA and incubated for 48 h, and then cells were treated
with 100 ng/mL IGF-I. After 1.5 h (Twist1) or 12 h (CLU), quantitative RT-PCR was performed using
the primer pairs and probes for Twist1, CLU and GAPDH. Each transcript level from non-treated cells
was set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with no treatment). (B) LNCaP (left) and
PC-3 (right) cells were transfected with 40 nM of the indicated siRNA and incubated for 48 h, and
then cells were treated with 100 ng/mL IGF-I. After the indicated duration, whole-cell extracts were
analyzed by SDS–PAGE and western blot analysis with specific antibodies. (C) LNCaP cells were
cotransfected with 0.5 μg/mL of the CLU–Luc –1,998/+254 plasmid, 20 nM of the indicated siRNA
and 0.05 μg/mL of pRL-TK, incubated for 24 h, and then cells were and treated with IGF-I. After 24 h,
the luciferase activity of CLU–Luc –1,998/+254 transfected with control siRNA without IGF-I was
set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with no treatment).
25
Figure 4. IGF-I activates STAT3, resulting in Twist1 up-regulation. (A) LNCaP cells were treated
with 100 ng/mL IGF-I. After the indicated duration, whole-cell extracts were analyzed by
SDS–PAGE and western blot analysis with specific antibodies. (B) LNCaP cells were treated with
100 ng/mL IGF-I. After 30 min, cells were harvested and fractioned into nuclear and cytoplasmic
extracts, and then extracts were analyzed by SDS–PAGE and western blot analysis with specific
antibodies. (C) ChIP assays were performed on nuclear extracts from LNCaP cells treated with 100
ng/mL IGF-I for 30 min using mouse IgG or anti-STAT3 antibody. The quantitative RT-PCR was
performed using immunoprecipitated DNAs, soluble chromatin and specific primer pairs for the
Twist1-promoter region. Results of immunoprecipitated samples were corrected for the results of the
corresponding soluble chromatin samples. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with no
treatment). **P < 0.05 (compared with treatment with IGF-I). (D) ChIP assays were performed on
nuclear extracts from LNCaP cells treated with 100 ng/mL IGF-I for 6 h using mouse IgG or
anti-Twist1 antibody. The quantitative RT-PCR was performed using immunoprecipitated DNAs,
soluble chromatin and specific primer pairs for the CLU-promoter region. Results of
immunoprecipitated samples were corrected for the results of the corresponding soluble chromatin
samples. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with no treatment). (E) LNCaP cells were
cotransfected with 0.5 μg/mL of Twist–Luc plasmid and 0.05 μg/mL of pRL-TK, incubated for 36 h
(Twist1), and then cells were treated with 100 ng/mL IGF-I. After 4 h (Twist1), the luciferase activity
of Twist–Luc without IGF-I was set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with no
treatment.
Figure 5. IGF-I/Twist1/CLU signaling in IGF-I-deficient mice. (A) Serum IGF-I concentration was
measured from PTEN knockout lit/+ mice and PTEN knockout lit/lit mice. Boxes, mean; bars, ±s.e.m.
*P < 0.05 (compared with lit/+). (B) Quantitative RT-PCR was performed using the primer pairs and
probes for murine Twist1, murine CLU and murine GAPDH. Each transcript level from lit/+ mice was
set as 1. Boxes, mean; bars, ±s.e.m. *P < 0.05 (compared with lit/+). (C) Immunohistochemistry
26
against the indicated antibodies in prostate tissues from PTEN knockout lit/+ mice and PTEN
knockout lit/lit mice was shown.
Figure 6. IGF-I promotes prostate cancer cell growth in IGF-I-deficient serum through Twist1 and
CLU. (A) LNCaP cells transfected with 10 nM of the indicated siRNA were cultured in 1% serum
from lit/lit or lit/+ mice (left), or 1% serum from lit/lit mice with or without 100 ng/mL IGF-I (right).
After 96 h, growth of cells transfected with control siRNA and cultured in 1% serum from lit/lit mice
was set as 1. Boxes, mean; bars, ±s.d. *P < 0.05 (compared with lit/lit or IGF-I–). **P < 0.05
(compared with control siRNA). (B) Schematic representation of signaling pathway from IGF-I to
CLU in this study.
Figure 1 Takeuchi et al.
0 6 12 24 IGF-I (h)0 6 12 24 IGF-I (h)
B
CLU
LNCaP
�-actin
Twist1
CLU
PC-3
�-actin
Twist1
A
0
0.5
1
1.5
2
2.5
3
3.5
4
0 h 1.5 h 6 h 12 h 24 h
Rela
tive m
RN
A e
xp
ressio
n LNCaP Twist1
CLU
IGF-I
*
*
** *
*
0
0.5
1
1.5
2
2.5
3
0 h 1.5 h 6 h 12 h 24 h
Rela
tive m
RN
A e
xp
ressio
n
PC-3 Twist1
CLU
IGF-I
**
*
**
**
*
Figure 2 Takeuchi et al.
-1998Luciferase+254
CLU-Luc -1998/+254
-707Luciferase+254
CLU-Luc -707/+254
-1998Luciferase
-702CLU-Luc -1998/-702
-1116Luciferase
-702CLU-Luc -1116/-702
+1-2000 +500
CLE E-boxAP-1
ClusterinC
CLU
Twist1
�-actin
LNCaP
A
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Control
siRNA
Twist1
siRNA
#1
Twist1
siRNA
#2
Rela
tive m
RN
A e
xp
ressio
n
LNCaP Twist1
CLU
Twist
**
B
CLU
LNCaP
�-actin
IB;Myc
Twist1-Myc-Flag
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Myc-Flag Twist1-Myc-Flag
Rela
tive m
RN
A e
xp
ressio
n LNCaPCLU*
F
0
0.2
0.4
0.6
0.8
1
1.2
Control
siRNA
Twist1
siRNA #1
Twist1
siRNA #2
Rela
tive lu
cif
era
se a
cti
vit
y
LNCaP
CLU-Luc
**
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
CLU-Luc
-1998/+254
CLU-Luc
-1998/-702
CLU-Luc
-1116/-702
CLU-Luc
-707/+254
Rela
tive lu
cif
era
se a
cti
vit
y LNCaPD
*
0
0.5
1
1.5
2
2.5
CLU-Luc
-1998/+254
CLU-Luc
-1998/-702
CLU-Luc
-1116/-702
CLU-Luc
-707/+254
Rela
tive lu
cif
era
se a
cti
vit
y LNCaP Myc-FlagTwist1-Myc-Flag
E
* *
0
0.2
0.4
0.6
0.8
1
1.2
CLU -02 CLU -01 CLU +07 RPL30
Imm
un
op
rec
ipit
an
ts/in
pu
t
LNCaPIgG
Histone H3
Twist1
G
*
Figure 3 Takeuchi et al.
0 6 12 24 0 6 12 24 IGF-I (h) 0 6 12 24 0 6 12 24 IGF-I (h)
Twist1
�-actin
Control
siRNA
CLU
Twist1
siRNA #1
LNCaPB
Twist1
�-actin
Control
siRNA
CLU
Twist1
siRNA #1
PC-3
C
IGF-I
0
0.5
1
1.5
2
2.5
3
3.5
+
Rela
tive lu
cif
era
se a
cti
vit
y
LNCaP
CLU-Luc
Control siRNATwist1 siRNA #1
*
0
0.5
1
1.5
2
2.5
3
3.5
+
Rela
tive m
RN
A e
xp
ressio
n
LNCaP
Twist1
Control siRNATwist1 siRNA #1
IGF-I
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
+
Rela
tive m
RN
A e
xp
ressio
n
LNCaP
CLU
Control siRNATwist1 siRNA #1
IGF-I
0
0.5
1
1.5
2
2.5
+
Rela
tive m
RN
A e
xp
ressio
n
PC-3
Twist1
Control siRNATwist1 siRNA #1
IGF-I
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
+
Rela
tive m
RN
A e
xp
ressio
n
PC-3
CLU
Control siRNATwist1 siRNA #1
IGF-I
A
* *
**
0
0.5
1
1.5
2
2.5
LNCaP Ctrl LNCaPIGF (6h)
Imm
un
op
rec
ipit
an
t/in
pu
t
LNCaP
CLU -02
D
IGF-I
*
0 15 30 60 IGF-I (min)
A
�-actin
LNCaP
p-STAT3Tyr705
STAT3
p-STAT3Ser727
– + IGF-I
B
N
STAT3
C N C
LNCaP
Lamin B1
�-actin
Figure 4 Takeuchi et al.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
IgG STAT3
Imm
un
op
rec
ipit
an
t/in
pu
t LNCaP
Twist1 promoter
IGF-I
IGF-I+
C
*
0
0.5
1
1.5
2
2.5
+
Rela
tive lu
cif
era
se a
cti
vit
y LNCaP
Twist-Luc
IGF-I
E
*
– +
Figure 5 Takeuchi et al.
0
50
100
150
200
250
300
lit/+ lit/lit
Seru
m IG
F-I
co
ncen
trati
on
(ng
/mL
)
Serum IGF-IA
*
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
lit/+ lit/lit
Rela
tive m
RN
A e
xp
ressio
n
Twist1
CLU
B
*
CLU IGF-IR p-STAT3Tyr705 Twist1
lit/
+ m
ice
lit/
lit
mic
e
C
Figure 6 Takeuchi et al.
A
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Control
siRNA
Twist1
siRNA #1
CLU
siRNA
Rela
tive c
ell
gro
wth
LNCaP
lit/litlit/+*
** **
Media
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Control
siRNA
Twist1
siRNA #1
CLU
siRNA
Rela
tive c
ell
gro
wth
LNCaP
IGF-I IGF-I+
*
** **
Media
IGF-I
IGF-IR
Nucleus
STAT3 CLUTwist1
STAT3
Twist1
IGF-I IGF-I
Cancer cell
growth
P
P
B
27
Highlights
� Insulin-like growth factor-I (IGF-I) transcriptionally increased Twist1 levels as well as
clusterin (CLU) expression.
� At transcriptional level, Twist1 regulated CLU expression and mediated CLU induction by
IGF-I.
� As upstream pathway of Twist1, STAT3 mediated Twist1/CLU induction by IGF-I.
� Twist1 and CLU expressions were suggested to be lower in IGF-I–deficient mice.
� Both Twist1 and CLU knockdown suppressed prostate cancer cell proliferation promoted
by IGF-I.